NCT06485635View on ClinicalTrials.gov

Real-life-persistence to Antifibrotic Treatments

Active, not recruitingOBSERVATIONAL
Enrollment

10,646

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Nintedanib

Nintedanib

DRUG

Pirfenidone

Pirfenidone

Trial Locations (1)

92100

Clinityx, Boulogne-Billancourt

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY